Low risk area : PT comprises of a single dose of Chloroquine phosphate
10 mg / Kg. body weight to all fever / suspected malaria cases.
Age groups
Chloroquine Tablets
(150 mg. base)
No. of Tablets
(150 mg)
Below 1 year
75 mg.
1/2
1 to 4 years
150 mg.
1
5 to 8 years
300 mg.
2
9 to
14 years
450 mg.
3
Above 15 years
600 mg.
4
High Risk area
As per revised policy of NVBDCP presumptive treatment
of all suspected malaria cases, upto sub - center level only, in "High
Risk Areas" (as defined in the MAP 95) is as follows
Chloroquine base
Day 1
10 mg / Kg ( 600 mg
adult)
Primaquine
Day 1
0.75 mg / kg ( 45 mg adult)
Chloroquine base
Day 2
10 mg / kg (600 mg adult)
Chloroquine base
Day 3
5 mg / kg (300 mg adult)
Dosage as per age groups
Age in years
Day 1
Day 2
Day 3
C.quine
(150 mg base)
P.quine (7.5
mg)
C.quine
(150 mg base)
C.quine
(150 mg base)
<1
1/2
0
1/2
1/4
1-4
1
1
1
1/2
5-8
2
2
2
1
8-14
3
4
3
1½
>14
4
6
4
2
2. Radical treatment
Blood smears collected are examined in the laboratories. On examinations,
one day radical treatment is given to Pf cases and 5 days radical
treatment to P. Vivax as per the age group given below.
Low Risk area :
Plasmodium Vivax
Age in years
Chloroquine Phosphate
(150 mg base) Single dose
Primaquine (2.5 mg
base ) daily dose for 5 days
mg base
No. of tablets
mg base
No. of tablets
< 1
75 mg.
½
Nil
Nil
1-4
150 mg.
1
2.5
1
5-8
300 mg.
2
5.0
2
8-14
450 mg.
3
10.0
4
> 14
600 mg.
4
15.0
5
Plasmodium falciparum
In "Low Risk Areas" where presumptive treatment with 600
mg chloroquine alone (adult dose) has been given and later blood smear
is found positive for pf, the complete radical treatment should be given
with a single dose of tablet chloroquine 10 mg / Kg bw combined with
0.75 mg / kg bw of primaquine.
High Risk Area : In high risk areas where presumptive treatment with
1500 mg chloroquine base spread over three days and 45 mg primaquine
(adult dose) has been given, chloroquine need not be administered again,
but primaquine must be given for 5 days.
Age in years
Primaquine (2.5 mg base )
daily dose for 5 days
mg base
No. of tablets
< 1
Nil
Nil
1-4
2.5
1
5-8
5.0
2
8-14
10.0
4
> 14
15.0
6
Plasmodium falciparum : In High Risk areas, fever cases are given presumptive
treatment with 1500 mg Chloroquine (Over 3 days) and 45 mg primaquine
(adult single dose). Therefore radical treatment with primaquine is
not required if they are found positive for pf microscopically.
Age groups
Radical Treatment
PV
Pf
1st day
2- 5 days
1st day
C.quine (mg)
P.quine (mg)
P.quine (mg)
C.quine (mg)
P.quine
(mg)
Below 1 year
75
--
--
75
--
1 to 4 years
150
2.5
2.5
150
7.5
5 to 8 years
300
5.0
5.0
300
15
9 to 14 years
450
10.0
10.0
450
30
Above 15 years
600
15.0
15.0
600
45
N.B.: No radical treatment of Primaquine tablets is given to infants
and Pregnant women..
In High Risk Areas
One day radical treatment to fever cases in the form of 1,500
mg Chloroquine + 45 mg primaquine and mass suppressive treatment in
the form of 600 mg chloroquine + 45 mg primaquine will be given to treat
asymptomatic carriers.
State has made major innovation in treatment of malaria cases which
can be enumerated below.
a) Twin-pack :- Tablet Chloroquine contains 150 mg. base and tablet
Primaquine is available in 2.5, 7.5 mg. strength. For giving presumptive
treatment to an adult case, nearly 4 tablet of Chloroquine and 6 to
18 tablets of Primaquine (depending on contents) are to be given. State
has noticed non response to such presumptive treatment and innovated
a “Twin-pack” containing tablet Chloroquine 600 mg. and
tablet Primaquine 45 mg. This has greatly reduced the non response and
increased the consumption of tablets. This in turn helped in reducing
parasitic load in the community.
b) Introduction of 1500 mg. Chloroquine in 3 divided doses and Primaquine
45 mg. as condensed Radical Treatment to all suspected cases of malaria
in high risk area.
c) Availability of Sulfadoxin-Pyrimethamine tablets at Primary Health
Centers and community health centers for treatment of suspected Chloroquine
resistance cases.
d) For faster recovery state has made available Artisunate Injection
at referral institutions.
